<DOC>
	<DOCNO>NCT01942382</DOCNO>
	<brief_summary>The purpose study evaluate pharmacokinetics ( study body drug ) safety paliperidone palmitate range 75 150 milligram equivalent repeat dos ( 4 injection ) administer deltoid muscle ( muscle shoulder ) gluteal muscle ( group muscle present buttock ) participant schizophrenia .</brief_summary>
	<brief_title>A Clinical Pharmacology Study JNS010 ( Paliperidone Palmitate ) Patients With Schizophrenia</brief_title>
	<detailed_description>This multicenter ( study conduct multiple site ) , open label ( people know identity intervention ) , randomize ( study medication assign chance ) , parallel-group ( group participant treat time ) study . Approximately , 60 participant enrol study . This study consist screen phase ( maximum 14 day ) , observation phase ( 92 day ) , follow-up phase ( 98 day ) . Participants randomly assign treatment group A , B , C. During observation phase , participant receive injection paliperidone palmitate concentration range 75 150 milligram equivalent deltoid muscle gluteal muscle applicable Days 1 , 8 , 36 , 64 alternate side ( left/right ) . Safety evaluation include assessment adverse event , clinical laboratory test , electrocardiogram , vital sign , physical examination , injection site reaction , drug-induced extrapyramidal symptom scale , visual analog scale evaluate throughout study . The total study duration participant approximately 190 day .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Paliperidone Palmitate</mesh_term>
	<criteria>Participants capability provide inform consent write participate study Participants diagnosis schizophrenia accordance diagnostic criterion Diagnostic Statistical Manual Mental Disorders IVTR ( DSMIVTR ) Participants whose psychiatric symptom consider stable investigator/subinvestigator time give informed consent Participants Positive Negative Syndrome Scale ( PANSS ) score less equal 4 ( moderate ) follow 9 item screen : delusion , conceptual disorganization , hallucinatory behavior , excitement , grandiosity , suspiciousness/persecution , hostility , uncooperativeness , poor impulse control Participants experience take risperidone formulation paliperidone formulation 8 day initial day ( Day 1 ) study treatment DSMIVTR diagnosis schizophrenia DSMIVTR diagnosis substancerelated disorder within 180 day date screening At risk suicide otherinjurious behavior consider investigator/subinvestigator , participant history suicide attempt Concurrent condition Parkinson 's disease ( except druginduced extrapyramidal syndrome ) Concurrent condition history symptomatic cerebrovascular accident</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>JNS010</keyword>
	<keyword>Paliperidone Palmitate</keyword>
	<keyword>Clinical Pharmacology</keyword>
</DOC>